Avelumab treatment characteristics
| Treatment on the index date | Patients, n | Follow-up period, median (95% CI), months | Treatment discontinuation (avelumab), n (%) | TTD (avelumab), median (95% CI), months |
| Avelumab only or avelumab+systemic therapy | 90 | 20.8 (19.1 to 24.2) | 52 (57.8) | 13.5 (6.4 to 30.6) |
| Avelumab only | 86 | 20.8 (19.1 to 24.2) | 52 (60.5) | 12.0 (9.3 to 30.5) |
| Avelumab+systemic therapies (carboplatin and etoposide) | 4 | 17.5 (17.4 to NE) | 0 | NE (NE to NE) |
| Patients received avelumab as 1L treatment | 73 | 21.3 (19.6 to 25.3) | 38 (52.1) | 24.5 (7.4 to 37.7) |
| Patients received avelumab as 2L+ treatment | 17 | 18.17 (12.0 to 20.8) | 14 (92.4) | 3.4 (1.8 to 13.5) |
1L, first line; 2L+, second or later line; NE, not estimable; TTD, time until treatment discontinuation.